Company Profile Biotecnol is a biopharmaceutical

Company: Biotecnol – Serviços e Desenvolvimento, S.A.
Contact: Prof. Pedro de Noronha Pissarra
Address: Lagoas Park, Edifício 7, 1ºNorte; Porto Salvo, 2741 - 901 Oeiras
E-mail: [email protected]
Telephone: +351 21 422 0520
Company Profile
Biotecnol is a biopharmaceutical company specialized on the development of antibodybased therapeutics to treat life-threatening diseases such as cancer.
Biotecnol applies a product development and manufacturing experience to generate,
support and potentially license human antibody products with Tribody™ technology.
Biotecnol is committed to build value by developing a diverse pipeline of antibody
products to address an unmet healthcare need. Biotecnol also leverages its own
business income by establishing in-house partner-led programs. Biotecnol uses
proprietary expression technology, cell line development capabilities, upstream and
downstream processing, analytics and QC experience for delivering GMP/GLP
compliant processes for bio manufacturing. Biotecnol has several internal development
programs in oncology and a strong client-based activity with established track-record.
Biotecnol has important alliances with international partners for the development of
vaccine against cancer, such as ImmunoDesign Molecules, Inc (USA), Pharma
Company (USA), VIB (Belgium) and University of Naples (Italy).
CEO and Management Team
The management team is composed by graduated and qualified members as Pedro de
Noronha Pissarra, Luís Amado, Andrew Kelly, and Philip Cunnah.
Pedro de Noronha Pissarra, CEO, has doctorate in Biotechnology by Kings College of
University of London. He worked at biotechnology department of University of Denmark
(Lyngby) and at chemistry department of MI.I.T (USA). He also worked in several
companies like EuropaBio, APBio, Biotech & Finance Forum, Vida Rhein, SA and
Conselho Superior de Ciência Tecnologia e Inovação.
Company creation date: November 1996
Number of employees: 25
Intervention of PME Investimentos: 1.102.000 Euro
January 2006